Compare LCID & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCID | IRON |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | N/A | N/A |
| Metric | LCID | IRON |
|---|---|---|
| Price | $11.20 | $78.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $24.00 | ★ $110.08 |
| AVG Volume (30 Days) | ★ 8.6M | 537.0K |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,065,533,000.00 | N/A |
| Revenue This Year | $64.76 | N/A |
| Revenue Next Year | $84.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 45.86 | N/A |
| 52 Week Low | $9.50 | $30.82 |
| 52 Week High | $35.90 | $99.50 |
| Indicator | LCID | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 48.41 |
| Support Level | $10.55 | $74.42 |
| Resistance Level | $11.69 | $82.26 |
| Average True Range (ATR) | 0.64 | 3.70 |
| MACD | 0.14 | 0.83 |
| Stochastic Oscillator | 65.28 | 72.31 |
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.